Cost and access dynamics of JAK inhibitors utilized for dermatologic care DOI Creative Commons
Joseph Visingardi,

Bryan Sherwood

Journal of Generic Medicines The Business Journal for the Generic Medicines Sector, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 24, 2024

Janus Kinase (JAK) inhibitors may offer a more cost effective option for patients rather than biologics. This study sought to investigate if market competition has reduced the price and expanded access those on JAK inhibitors. We utilized CMS Medicare spending data from 2018 2022 costs per dose, beneficiary change in total beneficiaries over time. Over this time frame baricitinib had 26% dose increase, 237% increase medication 210% beneficiary. Upadacitinib an 18% 1341% 289% Ruxolitinib 0.8% 1534% brand 57% Tofacitinib 28% 10% reduction 35% XR 30% 60% Overall utilization each of medications increased despite biologics black box warning these elderly population. class medications, its risks, still not be most cost-effective individual broader healthcare system.

Language: Английский

Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review DOI Creative Commons
Miguel Mansilla‐Polo, D. Morgado‐Carrasco

Dermatology and Therapy, Journal Year: 2024, Volume and Issue: 14(8), P. 1983 - 2038

Published: July 16, 2024

The risk of infections associated with biological drugs (BD) and Janus kinase inhibitors (JAKi) has been extensively explored in the literature. However, there is a dearth studies that evaluate both pharmacological groups together and, furthermore, compare them. Here, we review BD JAKi used dermatology.

Language: Английский

Citations

9
Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review DOI Creative Commons
Miguel Mansilla‐Polo, D. Morgado‐Carrasco

Dermatology and Therapy, Journal Year: 2024, Volume and Issue: 14(6), P. 1389 - 1442

Published: May 19, 2024

Biological drugs (BD) and Janus kinase inhibitors (JAKi) have revolutionized the treatment of diverse dermatoses. However, there are concerns regarding their safety, especially risk cancer opportunistic infections. Here, we discuss associated with BD JAKi used in dermatology. A narrative review was carried out. All relevant articles evaluating or published between January 2010 February 2024 were selected. Multiple large studies evaluated association BD, risk. is a lack prospective, comparative studies. Overall, patients undergoing present cutaneous incidence similar to that general population. The more strongly non-skin anti-tumor necrosis factor (anti-TNFs) agents (especially tofacitinib oral ruxolitinib). This appears increase age, presence other factors (such as chronic immunosuppression from previous comorbidities), specific diseases such rheumatoid arthritis (RA) myelodysplastic syndrome. Conversely, interleukin (IL)-17 IL-23 may even reduce some visceral hematological malignancies. In dermatological conditions psoriasis atopic dermatitis, malignancies be lower than subgroups, probably comparable generally low. can higher elderly RA syndrome, those prolonged therapy ruxolitinib (oral), anti-TNF agents.

Language: Английский

Citations

3
Revolutionizing the management of patients with atopic dermatitis: practical considerations DOI Open Access
Filomena Russo, Anna Rita Giampetruzzi, Maria Pilla

et al.

Expert Opinion on Biological Therapy, Journal Year: 2024, Volume and Issue: 24(4), P. 213 - 215

Published: March 24, 2024

KEYWORDS: Atopic dermatitisdupilumabtralokinumabupadacitinibbaricitinibabrocitinibbiological therapiessmall molecules drugmanagement

Citations

1
Selecting first-line advanced therapy for ulcerative colitis: A clinical application of personalized medicine DOI Creative Commons
Mariam S Mukhtar, Mahmoud Mosli

Saudi Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: 30(3), P. 126 - 137

Published: April 10, 2024

Ulcerative colitis (UC) is a chronic autoimmune inflammatory disease that affects the colon, leading to symptoms of bloody diarrhea, abdominal cramps, and urgency. The treatment UC has evolved over past few decades from locally active anti-inflammatory compounds more selective therapies target specific arrays immune system. challenge selecting first advanced therapy became apparent in this rapidly expanding landscape medications. No current investigational tools, such as genetic, immunologic, or biological markers, can guide identification safest most effective therapeutic option for each patient. Hence, physicians must carefully assess patient/disease characteristics match them with suitable drug through clinically driven assessment. In paper, we outline patient play role first-line propose an algorithm selection.

Language: Английский

Citations

1
Tralokinumab in the Era of Disruption in Atopic Dermatitis DOI Creative Commons

Nicola Humphry

EMJ Dermatology, Journal Year: 2024, Volume and Issue: unknown, P. 103 - 111

Published: Nov. 7, 2024

While for some individuals with atopic dermatitis (AD), the disease can be controlled topical treatments, those moderate-to-severe AD often require systemic therapy long-term control. Systemic treatments include conventional agents, small molecule inhibitors, and biologics, each its own risks benefits. For example, agents carry significant use, inhibitors frequent dosing. Melinda Gooderham, SkiN Centre Dermatology, Probity Medical Research, Queen’s University, Peterborough, Canada; Marjolein de Bruin-Weller, University Center Utrecht, Netherlands; April Armstrong, of California, Los Angeles, USA, are internationally renowned specialists in AD. Here, they discuss how advent biologic has changed clinical practice. One more recent therapies to become available is tralokinumab. This administered as a single injection every 2 or 4 weeks, well-tolerated, used over long term without diminishing efficacy. Biologics such tralokinumab at forefront change from flare-driven treatment management on stable, basis, associated improvements health-related quality life (HRQoL) patients.

Language: Английский

Citations

1
Long-term safety of biologic and targeted synthetic disease modifying drugs in rheumatology DOI

Kaia Barth,

Harsimrat Gill, Namrata Singh

et al.

Current Opinion in Rheumatology, Journal Year: 2023, Volume and Issue: 36(2), P. 113 - 119

Published: Dec. 20, 2023

Purpose of review The landscape for treatment rheumatic diseases is ever evolving, with several new drugs recently approved across and more in the pipeline. This timely aims to highlight latest literature on long-term safety profiles salient established emerging biologic (b) targeted synthetic (ts) disease modifying antirheumatic (DMARDs). Recent findings risk infection remains elevated use most b tsDMARDs, specifically hepatitis B reactivation rituximab zoster JAK inhibitors (JAKi). results ORAL surveillance trial led black box warnings JAKi evoked critical risk-benefit discussions surrounding DMARDs overall. Summary Such well conducted trials are needed gather long term comparative data DMARDs. In interim, real world observational studies also have a role play our understanding drug safety, provided that detailed attention paid minimize biases inherent studies.

Language: Английский

Citations

2
Pharmaceutical aspects of JAK inhibitors: a comparative review DOI
Sandhya Jinesh, Rajan Radhakrishnan

Inflammopharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 11, 2024

Language: Английский

Citations

0
Cost and access dynamics of JAK inhibitors utilized for dermatologic care DOI Creative Commons
Joseph Visingardi,

Bryan Sherwood

Journal of Generic Medicines The Business Journal for the Generic Medicines Sector, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 24, 2024

Janus Kinase (JAK) inhibitors may offer a more cost effective option for patients rather than biologics. This study sought to investigate if market competition has reduced the price and expanded access those on JAK inhibitors. We utilized CMS Medicare spending data from 2018 2022 costs per dose, beneficiary change in total beneficiaries over time. Over this time frame baricitinib had 26% dose increase, 237% increase medication 210% beneficiary. Upadacitinib an 18% 1341% 289% Ruxolitinib 0.8% 1534% brand 57% Tofacitinib 28% 10% reduction 35% XR 30% 60% Overall utilization each of medications increased despite biologics black box warning these elderly population. class medications, its risks, still not be most cost-effective individual broader healthcare system.

Language: Английский

Citations

0